Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: kruper l. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
Papillary carcinoma of the breast: an overview.
Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G. Pal SK, et al. Among authors: kruper l. Breast Cancer Res Treat. 2010 Aug;122(3):637-45. doi: 10.1007/s10549-010-0961-5. Epub 2010 Jun 4. Breast Cancer Res Treat. 2010. PMID: 20524058 Free PMC article. Review.
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.
Mortimer J, Jung J, Yuan Y, Kruper L, Stewart D, Chung S, Yu KW, Mendelsohn M, D'Apuzzo M, Tegtmeier B, Dadwal S. Mortimer J, et al. Among authors: kruper l. Breast Cancer Res Treat. 2014 Dec;148(3):563-70. doi: 10.1007/s10549-014-3190-5. Epub 2014 Nov 11. Breast Cancer Res Treat. 2014. PMID: 25385180 Free PMC article. Clinical Trial.
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
Shinde AM, Zhai J, Yu KW, Frankel P, Yim JH, Luu T, Kruper L, Vito C, Shaw S, Vora NL, Kirschenbaum M, Somlo G. Shinde AM, et al. Among authors: kruper l. Breast. 2015 Feb;24(1):18-23. doi: 10.1016/j.breast.2014.10.008. Epub 2014 Nov 20. Breast. 2015. PMID: 25467313 Free PMC article.
Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S. Kanaya N, et al. Among authors: kruper l. J Steroid Biochem Mol Biol. 2017 Jun;170:65-74. doi: 10.1016/j.jsbmb.2016.05.001. Epub 2016 May 3. J Steroid Biochem Mol Biol. 2017. PMID: 27154416 Free PMC article.
Time to Treatment: Measuring Quality Breast Cancer Care.
Polverini AC, Nelson RA, Marcinkowski E, Jones VC, Lai L, Mortimer JE, Taylor L, Vito C, Yim J, Kruper L. Polverini AC, et al. Among authors: kruper l. Ann Surg Oncol. 2016 Oct;23(10):3392-402. doi: 10.1245/s10434-016-5486-7. Epub 2016 Aug 8. Ann Surg Oncol. 2016. PMID: 27503492
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S. Hsu PY, et al. Among authors: kruper l. Clin Cancer Res. 2018 Jan 15;24(2):395-406. doi: 10.1158/1078-0432.CCR-17-1983. Epub 2017 Oct 27. Clin Cancer Res. 2018. PMID: 29079660 Free PMC article.
53 results